SCHEMBL358426

SCHEMBL358426

COc1ccc(Nc2c(N)cnc3ccc(Br)cc23)c(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.65
NCOA1 Q15788 1/20 0.65
NCOA3 Q9Y6Q9 1/20 0.65
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 3/20 0.45
HTT P42858 2/20 0.45
SRC P12931 3/20 0.44
RAB9A P51151 2/20 0.44
ABL1 P00519 2/20 0.43
GAK O14976 1/20 0.43
EPHB6 O15197 1/20 0.43
RIPK2 O43353 1/20 0.43
STK16 O75716 1/20 0.43
ACVR1 Q04771 1/20 0.43
AAK1 Q2M2I8 1/20 0.43
COQ8A Q8NI60 1/20 0.43
NLK Q9UBE8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL358516 0.85 NPC1 (0.66) NPC1NCOA1NCOA3ALDH1A1SMN1; SMN2
SCHEMBL30849390 0.83 MAPT (0.49) NPC1NCOA1NCOA3SMN1; SMN2MAPT
SCHEMBL29207180 0.83 MAPT (0.49) NPC1NCOA1NCOA3SMN1; SMN2MAPT
SCHEMBL358801 0.82 NPC1 (0.59) NPC1NCOA1NCOA3ALDH1A1SMN1; SMN2
SCHEMBL12983646 0.77 TNF (0.42) NPC1NCOA1NCOA3MAPTHTT
SCHEMBL31439396 0.76 CSF1R (0.47) SRCABL1GAKEPHB6RIPK2
SCHEMBL2246108 0.75 SRC (0.55) SMN1; SMN2MAPTSRCABL1EGFR
SCHEMBL5929807 0.75 CSF1R (0.64)
SCHEMBL12482516 0.74 PIK3CA (0.46) NPC1HTTRAB9AABL1GAK
SCHEMBL31439355 0.74 MAPT (0.47) NPC1NCOA1NCOA3ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062046-B2 Substituted imidazoquinoline derivatives as kinase inhibitors Piramal Enterprises Limited (IN) 2015-06-23 US disclosed
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP disclosed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US disclosed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS CDK2, CDK4, MAP3K1 NPC1 3676/4885NCOA1 776/4885NCOA3 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.